Pancreatic cancer is a devastating malignancy characterized by a high fatality rate,[1] primarily attributed to the formidable challenges in early diagnosis.[2] BRD4, a member of the Bromodomain and Extraterminal (BET) protein family, is a promising target for anticancer drugs due to its involvement in organizing super‐enhancers (SEs) and regulating the expression of oncogenes.[3] Inhibiting BRD4 disrupts the communication between SEs and target promoters, leading to the specific repression of oncogenes that cancer cells depend on for survival and ultimately resulting in cell death. The gene discussed is BRD4; the disease is familial pancreatic carcinoma.